Evogene (EVGN) EBIT (2012 - 2026)
Evogene (EVGN) posted EBIT of -$3.2 million for Q1 2026, up 39.56% sequentially from -$5.2 million in Q4 2025, and down 4.06% YoY from -$3.3 million in Q1 2025.
Evogene (EVGN) EBIT (2012 - 2026) Analysis & Trends
Evogene has reported EBIT for 15 years, with the latest figure at -$3.2 million in Q1 2026.
- Quarterly EBIT fell 4.06% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.2 million (up 17.0% YoY) and the FY2025 annual result came in at -$14.0 million, up 25.37% from the prior year.
- EBIT climbed to -$3.2 million in Q1 2026 per EVGN's latest filing, from -$5.2 million in the prior quarter.
- Over five years, EBIT peaked at -$2.7 million in Q3 2025 and troughed at -$8.1 million in Q1 2022.
- A 5-year average of -$5.2 million and a median of -$4.6 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT surged 56.49% in 2022, then tumbled 101.69% in 2023.
- Over 5 years, EBIT stood at -$3.8 million in 2022, then plunged by 101.69% to -$7.6 million in 2023, then jumped by 54.38% to -$3.5 million in 2024, then plunged by 49.77% to -$5.2 million in 2025, then soared by 39.56% to -$3.2 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$3.2 million, -$5.2 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15 Mn |
| Dec 31, 2025 | -5.21 Mn |
| Sep 30, 2025 | -2.72 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Mar 31, 2025 | -3.03 Mn |
| Dec 31, 2024 | -3.48 Mn |
| Sep 30, 2024 | -5.92 Mn |
| Jun 30, 2024 | -4.63 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -7.63 Mn |
| Sep 30, 2023 | -4.18 Mn |
| Jun 30, 2023 | -7.90 Mn |
| Mar 31, 2023 | -6.80 Mn |
| Dec 31, 2022 | -3.78 Mn |
| Sep 30, 2022 | -7.10 Mn |
| Jun 30, 2022 | -8.01 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Dec 31, 2021 | -8.69 Mn |
| Sep 30, 2021 | -8.56 Mn |
| Jun 30, 2021 | -7.45 Mn |